[1] Blanco Vela CI, Bosques Padilla FJ. Determination of ammonia concentrations in cirrhosis patients-still confusing after all these years? Ann Hepatol, 2011,10:S60-S65.
[2] Thomsen KL, Macnaughtan J, Tritto G, et al. Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. PLoS One, 2016,11:e0146076.
[3] Spacek LA, Strzepka A, Saha S, et al. Repeated measures of blood and breath ammonia in response to control, moderate and high protein dose in healthy men. Sci Rep, 2018,8:2554.
[4] Poh Z, Chang PEJ. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol, 2012,2012:480309.
[5] Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepa-tic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol, 2015,5:S7-S20.
[6] Shawcross DL. Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy? Expert Rev Gastroenterol Hepatol,2015,9:539-542.
[7] Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: A randomized, controlled trial. Gastroenterology, 2014,147:1327-1337.e3.
[8] Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy:Role of inflammation and oxidative stress. World J Gastroenterol, 2010,16:3347-3357.
[9] Rahul R, Saraswat VA, Dhiman RK. Gut microbiota: its role in hepatic encephalopathy. J Clin Exp Hepatol, 2015,5:S29-S36.
[10] Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology, 2015,148:719-731.e3.
[11] Gu DH, Kim MY, Seo YS, et al. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. Clin Mol Hepatol, 2018,24:319-330.
[12] Katsushima F, Takahashi A, Suzuki T, et al. A case of overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis with marked elevation of IgM. Fukushima J Med Sci, 2013,59:63-67.
[13] Takaya H, Uemura M, Fujimura Y, et al. ADAMTS13 activity may predict the cumulative survival of patients with liver cirrhosis in comparison with the Child-Turcotte-Pugh score and the model for end-stage liver disease score. Hepatol Res, 2012,42:459-472.
[14] Ali E Z, Khalid MKNM, Yunus Z M, et al. Carbamoylp-hosphate synthetase 1 (CPS1) deficiency: clinical, biochemical, and molecular characterization in Malaysian patients. Eur J Pediatr, 2016,175:339-346.
[15] 李晓光, 于永光, 王丽艳,等. 血氨检测在临床肝脏疾病中的应用价值. 国际检验医学杂志, 2012, 33:1340-1342.
[16] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南.中华内科杂志,2018,57:705-718.
[17] Tsai CF, Chen MH, Wang YP, et al. proton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in population study. Gastroenterology, 2017,152:134-141.
[18] Singh J, Sharma BC, Puri V, et al. Sleep disturbances in pati-ents of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. Metab Brain Dis, 2017,32:595-605.
[19] Johnson PJ, Berhane S, Kagebayashi C, et al. assessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach—the ALBI grade. J Clin Oncol, 2015,33:550-558.
[20] Chen R C, Cai Y J, Wu J M, et al. Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis. J Viral Hepat, 2017,24:238-245.
[21] 侯玉丽, 高梦丹, 郭鸿雁,等. 白蛋白-胆红素指数与血氨联合检测对肝硬化并发肝性脑病的诊断价值评估. 中华医学杂志, 2018,98:127-131.
[22] 侯玉丽, 郭鸿雁, 王忠,等. APRI与血氨联合对肝硬化并肝性脑病的诊断价值评估. 北京医学, 2018,40:289-292.
[23] 龙莉. 肝性脑病患者血氨水平相关因素分析. 南昌大学, 2013.
[24] 张靖, 张厚亮. 肝硬化致肝性脑病患者血氨与血清白细胞介素-6水平相关性分析. 医学理论与实践, 2017, 30:1204-1206.
[25] 郑强, 刘世平, 贾家猛,等. 联合检测血氨与血清色氨酸在急诊肝性脑病患者中的临床应用. 川北医学院学报, 2016, 31:506-508. |
